1-5 of 5
Triparna Sen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

De Novo and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways

Subhamoy Chakraborty, Charles Coleman, Parvathy Manoj, Deniz Demircioglu, Nisargbhai Shah, Elisa de Stanchina, Charles M. Rudin, Dan Hasson, Triparna Sen
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (17): 3526–3540.
https://doi.org/10.1158/1078-0432.CCR-23-0471
Published: 01 September 2023
View article titled, <em>De Novo</em> and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways
Open the PDF for <em>De Novo</em> and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways in another window
Includes: Supplementary data
Journal Articles

Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer Exhibits Antitumor Efficacy with Low Toxicity

Kathryn M. Tully, Salomon Tendler, Lukas M. Carter, Sai Kiran Sharma, Zachary V. Samuels, Komal Mandleywala, Joshua A. Korsen, Avelyn Mae Delos Reyes, Alessandra Piersigilli, William D. Travis, Triparna Sen, Nagavarakishore Pillarsetty, John T. Poirier, Charles M. Rudin, Jason S. Lewis
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1391–1401.
https://doi.org/10.1158/1078-0432.CCR-21-1533
Published: 01 April 2022
View article titled, Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer Exhibits Antitumor Efficacy with Low Toxicity
Open the PDF for Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer Exhibits Antitumor Efficacy with Low Toxicity in another window
Includes: Supplementary data
Journal Articles

Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant Cancers

Carl M. Gay, Pan Tong, Robert J. Cardnell, Triparna Sen, Xiao Su, Jun Ma, Rasha O. Bara, Faye M. Johnson, Chris Wakefield, John V. Heymach, Jing Wang, Lauren A. Byers
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (1): 346–357.
https://doi.org/10.1158/1078-0432.CCR-18-1129
Published: 03 January 2019
View article titled, Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant Cancers
Open the PDF for Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant Cancers in another window
Includes: Supplementary data
Journal Articles

Abstract IA27: MYC drives molecular and therapeutically distinct subtype of SCLC

Gurkan Mollaoglu, Matthew R. Guthrie, Stefanie Bohm, Johannes Bragelmann, Milind D. Chalishazar, Abbie S. Ireland, Fang Huang, Zeping Hu, Robert J. Cardnell, Triparna Sen, Jason Gertz, Jane E. Johnson, Adi F. Gazdar, Lauren A. Byers, Ralph J. DeBerardinis, Robert J. Wechsler-Reya, Martin Sos, Trudy G. Oliver
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (17_Supplement): IA27.
https://doi.org/10.1158/1557-3265.AACRIASLC18-IA27
Published: 01 September 2018
View article titled, Abstract IA27: MYC drives molecular and therapeutically distinct subtype of SCLC
Journal Articles

Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer

Triparna Sen, Pan Tong, Lixia Diao, Lerong Li, Youhong Fan, Jennifer Hoff, John V. Heymach, Jing Wang, Lauren Averett Byers
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (20): 6239–6253.
https://doi.org/10.1158/1078-0432.CCR-17-1284
Published: 12 October 2017
View article titled, Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer
Open the PDF for Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer in another window
Includes: Supplementary data